ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,755.40
0.00%
S&P ASX All Technology
3,087.60
0.00%
Brent Oil
82.00
0.28%
US Dollar vs AUD
1.51352
0.00%
Bitcoin
67,457.19
-2.95%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AngioDynamics Inc (ANGO)

  7. AngioDynamics Inc (ANGO) News

ANGO

AngioDynamics (ANGO)

AngioDynamics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANGO
DateTimeSourceHeadlineSymbolCompany
22/05/202407:30Business WireAngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ SystemNASDAQ:ANGOAngioDynamics Inc
07/05/202406:45Business WireAngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific SessionsNASDAQ:ANGOAngioDynamics Inc
04/04/202422:31IH Market NewsUS Index Futures Rise, Oil Dips SlightlyNASDAQ:ANGOAngioDynamics Inc
04/04/202422:00Business WireAngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset DivestitureNASDAQ:ANGOAngioDynamics Inc
04/04/202421:45Business WireAngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PENASDAQ:ANGOAngioDynamics Inc
02/04/202408:26Business WireAngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.NASDAQ:ANGOAngioDynamics Inc
20/03/202407:01Business WireAngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024NASDAQ:ANGOAngioDynamics Inc
07/03/202408:01Business WireAngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services ConferenceNASDAQ:ANGOAngioDynamics Inc
05/03/202412:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANGOAngioDynamics Inc
16/02/202408:05Business WireAngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 MillionNASDAQ:ANGOAngioDynamics Inc
24/01/202408:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGOAngioDynamics Inc
24/01/202400:00Business WireAngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial DiseaseNASDAQ:ANGOAngioDynamics Inc
22/01/202423:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
11/01/202423:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
09/01/202408:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGOAngioDynamics Inc
05/01/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
05/01/202423:00Business WireAngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 GuidanceNASDAQ:ANGOAngioDynamics Inc
22/12/202308:01Business WireAngioDynamics to Present at the J.P. Morgan Healthcare ConferenceNASDAQ:ANGOAngioDynamics Inc
08/12/202308:01Business WireAngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024NASDAQ:ANGOAngioDynamics Inc
08/12/202300:00Business WireAngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismNASDAQ:ANGOAngioDynamics Inc
08/11/202300:03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ANGOAngioDynamics Inc
07/10/202305:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGOAngioDynamics Inc
06/10/202308:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGOAngioDynamics Inc
04/10/202322:22IH Market NewsWednesday’s Wall Street Highlights: Apple, Intel, Cal-Maine, A10 Networks, and moreNASDAQ:ANGOAngioDynamics Inc
04/10/202322:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
04/10/202322:00Business WireAngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 GuidanceNASDAQ:ANGOAngioDynamics Inc
22/09/202311:28Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202311:23Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202311:17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202311:12Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
 Showing the most relevant articles for your search:NASDAQ:ANGO

Your Recent History

KOSPI
381970
K Car
BOV
GMAT3M
Grupo Mateus ON
LSE
FD09
Citi Fun 24
AQSE
AIEA.GB
Airea
TSX
SLS
Solaris Resources
BOV
VVCR11
Units
NYSE
TOO-A
Teekay Offshore Partners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved